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Abstract
Allogeneic hematopoietic cell transplantation (HCT) represents a vital procedure for patients 
with various hematologic conditions. Despite advances in the field, HCT carries significant 
morbidity and mortality. A rare but potentially devastating complication is transplantat
associated  thrombotic  microangiopathy  (TA
etiology is attributed to deficient activity of ADAMTS13, (a member of the 
Metalloprotease with Thrombo
TA-TMA have > 5% ADAMTS13 activity. Pathophysiologic mechanisms associated with TA
TMA, include loss of endothelial cell integrity induced by intensive conditioning regimens, 
immunosuppressive  therapy,  irradiation,  infections  and  graft
The reported incidence of TA
accurate  diagnosis  in  these  patients.  Two  different  groups  have  proposed  consensus 
definitions for TA-TMA, yet they fail to distinguish the primary syndrome from secondary 
causes such as infections or medication exposure. Despite treatment, mortality rate in TA
TMA  ranges  between  60%  to  90%.  The  treatment  strategies  for  TA
challenging.  Calcineurin  inhibitors  should  be  discontinued  and  replaced  with  alternative 
immunosuppressive agents.  Daclizumab, a humanized monoclonal anti
shown  promising  results  in  the  treatment  of  TA
defibrotide, have been reported to induce remission in this patient population. In general, 
plasma exchange is not recommended.    
Introduction:  Allogeneic  hematopoietic  cell 
transplantation  (HCT)  is  a  useful  therapeutic 
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oietic cell transplantation (HCT) represents a vital procedure for patients 
with various hematologic conditions. Despite advances in the field, HCT carries significant 
morbidity and mortality. A rare but potentially devastating complication is transplantat
associated  thrombotic  microangiopathy  (TA-TMA).  In  contrast  to  idiopathic  TTP,  whose 
etiology is attributed to deficient activity of ADAMTS13, (a member of the 
hrombospondin 1 repeats family of metalloproteases), patients with 
TMA have > 5% ADAMTS13 activity. Pathophysiologic mechanisms associated with TA
TMA, include loss of endothelial cell integrity induced by intensive conditioning regimens, 
rapy,  irradiation,  infections  and  graft-versus-host  (GVHD)  disease. 
The reported incidence of TA-TMA ranges from 0.5% to 75%, reflecting the difficulty of 
accurate  diagnosis  in  these  patients.  Two  different  groups  have  proposed  consensus 
TMA, yet they fail to distinguish the primary syndrome from secondary 
causes such as infections or medication exposure. Despite treatment, mortality rate in TA
TMA  ranges  between  60%  to  90%.  The  treatment  strategies  for  TA
rin  inhibitors  should  be  discontinued  and  replaced  with  alternative 
immunosuppressive agents.  Daclizumab, a humanized monoclonal anti
shown  promising  results  in  the  treatment  of  TA-TMA.  Rituximab  or  the  addition  of 
n reported to induce remission in this patient population. In general, 
plasma exchange is not recommended.    
Allogeneic  hematopoietic  cell 
transplantation  (HCT)  is  a  useful  therapeutic 
modality for a wide range of hematologic and non
hematologic  conditions.
1-
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TMA ranges from 0.5% to 75%, reflecting the difficulty of 
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TMA, yet they fail to distinguish the primary syndrome from secondary 
causes such as infections or medication exposure. Despite treatment, mortality rate in TA-
TMA  ranges  between  60%  to  90%.  The  treatment  strategies  for  TA-TMA  remain 
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progenitor cell collection, the new ‘gold standard’ 
in  hematopoietic  cell  harvesting,  and  non-
myeloablative  peripheral  blood  progenitor  cell 
transplantation,    have  reduced  treatment-related 
mortality  and    enabled  an  increasing  number  of 
patients with comorbid conditions as well as older 
patients  to  receive  therapy for  conditions such as 
acute  leukemia,  myelodysplastic  syndrome, 
multiple myeloma and lymphoma. The obstacles to 
successful HCT include the development of acute 
and  chronic  graft-versus-host  disease  (GVHD), 
opportunistic  infections,  and  other  complications, 
one  of  which  is  transplantation-associated 
thrombotic  microangiopathy  (TA-TMA).
4-6 The 
etiologies  of  this  syndrome  are  diverse,  and 
diagnosis  of  TA-TMA  in  this  patient  population 
requires  a  high  degree  of  clinical  suspicion. 
Moreover,  management  of  TA-TMA  remains  a 
challenging task, mainly due to the poor response to 
therapeutic  modalities  that  are  beneficial  in  non-
transplant-associated TMA.
Pathologic  and  clinical  features:  TMAs  are 
defined  by  the  association  of  microangiopathic 
hemolytic anemia, thrombocytopenia (platelet count
< 100x10
9/L) and ischemic manifestations related to 
the  formation  of  platelet-rich  thrombi  in  the 
microcirculation.
7 TMAs  include  thrombotic 
thrombocytopenic  purpura  (TTP),  and  the 
hemolytic-uremic syndrome (HUS), and variants of 
these,  which  are  characterized  by  ischemic 
manifestations  involving  the  brain  or 
gastrointestinal tract and/or kidneys, respectively.
8
TMA may be primary, or occur secondary to other 
disorders  such  as  pregnancy,  infections, 
autoimmune diseases and the post-HCT state.
9
The  clinical presentation  of  TMA  invariably 
includes  the  presence  of  schistocytes  on  the 
peripheral  blood  film  and  consumptive 
thrombocytopenia. Surrogate markers include DAT 
(direct  antiglobulin  test)-negative  hemolytic 
anemia,  an  elevated  serum  lactate  dehydrogenase
(LDH),  decreased  serum  haptoglobin  and  indirect 
hyperbilirubinemia. Coagulation studies are usually 
normal.  A  “pentad”  of  signs  and  symptoms  was 
traditionally  associated  with  classic  TTP: 
thrombocytopenia,  microangiopathic  hemolytic 
anemia  (MAHA),  neurologic  abnormalities,  renal 
abnormalities  and  fever.  This  complete  set  of 
symptoms occurs in only 40% of patients, and more 
than  70%  have  only  the  triad  of  MAHA, 
thrombocytopenia,  and  neurologic  changes  at  the 
time  of  diagnosis.
10 In  current  clinical  practice, 
thrombocytopenia,  schistocytosis,  and  an  elevated 
serum  LDH  in  the  appropriate  clinical  setting 
provide  sufficient  criteria  for  the  diagnosis.
7 The 
clinical manifestations of HUS are similar to TTP, 
although  renal  abnormalities,  as  opposed  to 
neurologic dysfunction, often predominate. 
Presentation  of  TA-TMA  is  similar  to  other 
forms  of  TMA;  multiple  contributing  pathogenic 
factors  have  been  implicated.
4,11 These  include 
endothelial  cell  injury  due  to  toxic  conditioning 
regimens (high-dose chemotherapy and total-body 
irradiation  [TBI]),  cytomegalovirus  (CMV) 
infection, the use of calcineurin inhibitors such as 
cyclosporine, and a possible graft-versus-host effect 
on  the  endothelium.
4,12-14 Because  anemia, 
thrombocytopenia,  renal  impairment,  and  changes 
in mental status are common and may have multiple 
causes in the transplant population, diagnosis may 
be  difficult.
15 This  observation  currently  is 
motivating  experts  in  the  field  to  reformulate  a 
classification  of  TMAs  more  focused  on 
pathophysiologic  mechanisms  rather  than  clinical 
symptoms.
16, 17
Diagnostic criteria: Until recently, there were no 
widely  accepted  criteria  for  the  definition  of 
hematopoietic progenitor cell TA-TMA. The Blood 
and  Marrow  Transplant  Clinical  Trials  Network 
(BMT CTN) and the International Working Group 
separately formed toxicity committees to develop a 
consensus  formulation  of  criteria  for  diagnosing 
clinically significant TA-TMA; these are listed in 
Table 1.
18,19
Incidence  and  risk  factors:  The  reported 
proportion  of  patients  developing  a  clinically 
significant TA-TMA syndrome has varied greatly. 
George  and  coworkers
15 presented  a  review  of 
published  reports  on  TMA  after  allogeneic  HCT. 
Twenty-eight different definitions of this syndrome 
have  been  used  in the  35  reviewed  reports. 
Reflecting the different definitions, the incidence of 
TA-TMA varied in these reports from 0.5 to 63.6% 
of  HCT  recipients,  the  median  frequency  of 
diagnosis being 7.9%. The mortality in the different 
series  ranged  from  0%  to  100%; the  overall 
mortality rate was 61%. Of the deceased patients, 
35  autopsy  reports  were  identified.  Three  of  the 
autopsies  attributed  death  to  HUS  due  to 
observation of isolated renal TMA. The remaining 
32 deaths were attributed to other causes, the most
common being systemic infection, including CMV,
Aspergillus  species,  adenovirus  and  human 
herpesvirus-6 (HHV-6). Eleven autopsies stated that
there  was  no  evidence of TTP-HUS.
15 In anotherMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Table 1: Diagnostic criteria for transplantation-associated TMA
Blood and Marrow Transplant Clinical Trials Network (BMT 
CTN) toxicity committee consensus definition for TMA
18
International Working Group Definition for TMA
19
All of the following are present:
1) RBC fragmentation and ≥ 2 schistocytes per high-power field 
on peripheral film
1) Increased  percentage  (>  4%)  of  schistocytes  in  the 
blood
2) Concurrent increased serum LDH above institutional baseline
2) De novo, prolonged or progressive thrombocytopenia 
(platelet count less than 5 x 109/l or a 50% or greater 
decrease from previous counts)
3) Concurrent renal
a and/or neurologic dysfunction without other 
explanations 3) Sudden and persistent increase in LDH
4) Negative direct and indirect Coomb’s test results
4) Decrease  in  hemoglobin  concentration  or  increased 
red blood cell transfusion requirement
5) Decrease in serum haptoglobin concentration
Abbreviations: LDH: lactate dehydrogenase; TMA: thrombotic microangiopathy; TA-TMA: transplantation-associated thrombotic 
microangiopathy.
aDoubling of serum creatinine from baseline (baseline=creatinine before hydration and conditioning) or 50% decrease in creatinine 
clearance from baseline.
review, Pettitt and Clark
4 estimated that TA-TMA 
occurs in 14% and 7% of allogeneic and autologous 
transplant  recipients,  respectively.  A  more  recent 
report of more than 4000 HCT recipients estimated 
the frequency of severe TA-TMA to be 0.5% and 
0.13%  of  allogeneic  and  autologous  recipients, 
respectively.
6 This varying incidence of TA-TMA 
among  reported  series  likely  reflects the  level  of 
physician  awareness,  the  different  diagnostic 
criteria,  and  the  heterogeneity  of  the  transplant 
population.
A  variety  of  potential  risk  factors  for  the 
development  of  TA-TMA  have  been  proposed 
(Table 2). Among the  earliest reports, the  use of
cyclosporine  (CsA)  for  the  prevention  of  GVHD 
was recognized as a potential culprit.
20,21 Intensive 
immunosuppression  with  other  inhibitors  of  the 
Ca
2+-activated  phosphatase,  calcineurin 
(tacrolimus),
22-24 and (TBI)
25 have been associated 
with TA-TMA as well. In the following section we 
examine  the  pathophysiology  and  clinical 
characteristics  of  both  primary  and  secondary 
TMAs.  The  heterogeneity  in  clinical  background 
(idiopathic  TTP  vs.  disease-associated  TMA, 
including  TA-TMA)  and  plasma  concentration  of
markers  (normal  vs.  decreased  ADAMTS13 
activity) is well emphasized and represents a barrier 
to the development of clear treatment guidelines. 
Pathophysiology 
Idiopathic TTP: Moake and colleagues
26 were the 
first  to  describe  the  presence  of    very  high 
molecular  weight  [so-called  ultralarge  (UL)] 
multimers of von Willebrand factor (vWF) in the 
plasma  of  a  patient  with  recurrent  TTP.  Once 
released  from  stimulated  endothelial  cells,  UL-
vWF,  not  present  in  plasma  from  healthy 
individuals,  promote  excessive  aggregation  of 
platelets, primarily  in  the  microvasculature. Some 
ULvWF multimers remain on the  endothelial cell 
surface as long strings that adhere to platelets. The 
molecules responsible for the binding of UL-vWF 
to  endothelial  cells  and  platelets  are  believed  to 
involve integrin αvβ3 and glycoprotein Ib (GpIb), 
respectively.
27 Microvascular  thrombosis  and 
hemolytic anemia occur particularly in high shear 
stress locations, such as the microvasculature, that 
results  in  unfolding  of  ULvWF  multimers  and 
exposure of platelet binding sites.
7,28
Moake hypothesized that a deficiency of a vWF 
cleaving  protease  might  be  responsible  for  the 
presence  of  ULvWF,
26 but  it  was  Furlan  and 
colleagues
29 et al., Tsai and Lian
30 who first isolated 
a plasma metalloprotease that cleaved the peptide 
bond  between  the  tyrosine  1605  and  methionine 
1606  in  the  central  A2  domain  of  vWF.  These 
investigators  subsequently  found  a  deficiency  of 
this vWF-cleaving protease in a retrospective cohort 
of patients clinically diagnosed as having TTP.
29,30
The protease was characterized in 2001 by Zheng 
and coworkers
31 as a new (the thirteenth) member 
of  the  ADAMTS  (A Disintegrin  And 
Metalloprotease  with  Thrombospondin  1  repeats) 
family  of  metalloproteases  and  was  thus  called 
ADAMTS13.
16,31-34 The  primary  role  of 
ADAMTS13 is to regulate the multimeric structure 
of vWF by cleaving the most hemostatically active 
ULvWF  multimers.
35 Failure  of  this  regulatory
mechanism  causes  the  highly  adhesive,  unusually 
large multimers of vWF to accumulate in plasma, 
which  may  lead  to  the  microvascular  thrombosis, 
tissue  ischemia  and  infarction  which  areMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Table 2: Potential risk factors for development of TA-TMA
Risk factor References
Female gender 21, 36, 122, 123
Older age 21, 36, 123
African American race 36
Advanced primary disease 124
Unrelated donor transplants 122-124, 126-128
HLA-mismatch (one or more loci) 124
Nonmyeloablative conditioning regimens 
(fludarabine-based regimens) 88, 129
High-dose busulfan (16mg/kg) 130
Total body irradiation 25, 123
Cyclosporine 14, 126, 131-133
Tacrolimus 24, 130, 132
Cyclosporine  and sirolimus 134, 135
Infections 124, 128
Acute GVHD 14, 21, 123, 124, 126, 128
Abbreviations: TA-TMA: transplantation-associated thrombotic microangiopathy; GVHD: graft-versus-host disease; HLA: human 
leukocyte antigen.
characteristic of TTP. 
The  estimated  annual  incidence  of  idiopathic 
TTP is 3.7 to 11 cases per million.
36 In extremely 
rare  cases,  severe  deficiency  of  ADAMTS13 
(defined  as <5%  serum  activity)  is  related  to 
compound heterozygous or homozygous mutations 
of  the  ADAMTS13  gene  (Upshaw-Shulman 
syndrome).
37-39 Defects  in  coding  of  the 
metalloprotease  gene,  located  on  chromosome 
9q34, result in functionally deficient enzyme. In the
vast  majority  of  cases,  severe  ADAMTS13 
deficiency is secondary to the development of anti-
ADAMTS13 autoantibodies that can be detected in 
vitro.
29,30 Functional  testing  often  is  employed  in 
which anti-ADAMTS13 autoantibodies are detected 
by their inhibitory effect on ADAMTS13 enzymatic 
activity.
40 More  recently,  physical  methods  of 
detection  have  been  used  and  identify  either 
immunoglobulin  G  (IgG)  or  IgM  species  via 
enzyme-linked  immunosorbent  assay  (ELISA).
41,42
In  more  than  80%  of  acquired  TTP,  anti-
ADAMTS13 antibodies are inhibitory IgG.
29,30 Less 
frequently, the mechanism for acquired TTP may be 
different, involving anti-ADAMTS13 noninhibitory 
IgG  or  IgM
41,42 autoantibodies  that  promote  the 
clearance  of  ADAMTS13  from  blood  without 
inhibiting its activity.
41
Adults  with  acquired  idiopathic  TTP  require 
daily plasma exchange until neurologic symptoms 
have resolved and both a normal serum LDH and 
platelet count have been maintained for at least 2 to 
3 days.
43-46 Plasma exchange is thought to remove 
antibodies against ADAMTS13, while replacing the 
deficient  protease.
47,48 Plasma  exchange  results  in 
the remission of TTP, which is usually fatal when 
untreated, in approximately 80%-90% of cases,
49-52
generally  without  persistent  organ  damage. 
Production of ADAMTS13 autoantibodies may also 
be  suppressed  by  high-dose  corticosteroid 
treatment,
52 although there is very little controlled 
data  that  demonstrates  efficacy  of  steroids  in  the 
treatment of idiopathic TTP. Other therapies include 
use  of  the  monoclonal  antibody  rituximab  that  is 
directed  against  the  CD20  epitope  on  B 
lymphocytes;  given  weekly  for  4-8  weeks,  this 
agent  will  eliminate  antibody-producing  cells
53-57
and  has  been  shown  to  induce  remission  in 
refractory TTP,  and  to  reduce the  otherwise high 
incidence  of relapse  in  these  patients.
56,58 Finally, 
splenectomy also has been shown to be effective in 
anecdotal cases of refractory TTP, and to reduce the 
incidence of relapse in small series. 
Hemolytic-uremic syndrome (HUS): HUS refers to 
TMA  that  primarily  affects  the  kidney,  often 
causing oliguric or anuric renal failure.
59 HUS may 
present with a variety of manifestations, with one 
variant  occurring  after  Escherichia  coli  O157:H7 
gastroenteritis,  primarily  in  children.
60 In  adults,
however,  HUS  occurs  most  commonly  in 
association with pregnancy, with more than 90% of 
cases  developing  in  the  postpartum  period.
61 The
characteristic histologic lesion of HUS consists of 
vessel  wall  thickening,  with  swelling  andMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Table 3: Primary and secondary thrombotic microangiopathies
Primary TMA Secondary TMA
- Hereditary TTP
- Idiopathic TTP
Immune-mediated
- Pregnancy
- Autoimmune disorders
- Infections
- Medications (clopidogrel, ticlopidine)
- Hereditary (atypical) HUS
- Sporadic (Shigatoxin-associated)
Non-immune mediated
- Malignant hypertension
- Solid organ transplantation
- HCT
- Metastatic tumors
- Medications  (cyclosporine,  tacrolimus,  IFN-α,   
Mitomycin C)
Abbreviations: TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; 
HCT: hematopoietic cell transplantation; IFN-α: interferon alpha.
detachment  of  the  endothelial  cells  from  the 
basement  membrane.  In  HUS,  microthrombi  are 
rich  in  fibrin  and  contain  relatively  little  vWF.
62
Their location is confined primarily to the kidneys 
and thus, renal failure is the dominant feature. HUS 
associated  with  renal  failure  in  the  absence  of  a 
diarrheal illness or other predisposing condition is 
commonly referred to as atypical HUS. It has been 
proposed  that  this  group  may,  in  part,  consist  of 
patients  with  complement  system  dysfunction 
owing  to  either  a  mutation  of  a  complement-
regulatory protein,
63 an antibody directed at one of 
these  proteins,
64 or  an  activating  mutation  of  a 
complement protein such as C3. Study of families 
with a history of HUS has implicated mutations in 
several  proteins  responsible  for  regulating  the 
alternative  complement  pathway,  namely 
complement factor H,
65 membrane cofactor protein 
(MCP),  and  factor  I  (IF),
66 as  well  as 
thrombomodulin.
67 Exposure  to  agents  potentially 
toxic to the vascular endothelium (such as certain 
viruses,  bacteria,  toxins,  immunocomplexes,  and 
cytotoxic  drugs)  may  initiate  local  intravascular 
thrombosis.
68 This  action  promotes  C3bBb 
convertase  formation  and  complement  deposition 
within capillary vessels.  Under normal conditions, 
however,  factor  H  may  effectively  limit 
complement deposition and further extension of the 
process  by  modulating  C3bBb  activity.
69 In 
contrast,  when  the  factor  H  bioavailability  is 
reduced due to decreased activity or is congenitally 
defective,  C3bBb  convertase  formation  and 
complement deposition may become uncontrolled. 
As  a  result,  the  microangiopathic  process  is 
extended,  leading  to  full-blown  manifestations  of 
the disease.    
Secondary TMA: Secondary forms of TMA refer to 
a  diverse  group  of  disorders  with  frequently 
overlapping  clinical  features  (Table  3).  An 
alternative  classification  that  takes  into 
consideration  the  underlying  pathophysiologic 
mechanisms  (immune-mediated  vs.  nonimmune-
mediated)  is  presented  here  (Table  4).  Immune-
mediated forms result from autoantibodies against 
ADAMTS13.
41,42,70 The  second  category 
(nonimmune-mediated)  occurs  from  massive 
endothelial cell stimulation with consequent release 
of  ULvWF  multimers  in  amounts  exceeding  the 
system’s degradative ability, despite the presence of 
normal  or  only  mildly  reduced  concentrations  of 
ADAMTS13.
71 Distinction  between  these  forms 
should limit diagnostic uncertainty and assist with 
management strategies,  namely  implementation of 
plasma  exchange  and  use  of  immunosuppressive 
therapy. 
The  most  common  physiologic  condition 
present  in  the  immune-mediated  forms,  which  is 
often  associated  with  severe  ADAMTS13 
deficiency, is pregnancy.
29,36,72,73 Immune-mediated 
TMA in pregnancy should be distinguished from a 
number  of  pregnancy-associated  TMAs  such  as 
preeclampsia,  hemolysis  with  elevated  liver 
enzymes  and  low  platelets  (HELLP)  syndrome, 
acute fatty liver of pregnancy, and antiphospholipid 
syndrome.
74,75 Accurate diagnosis is essential since 
plasma  exchange  is  indicated  for  pregnancy-
associated  TTP  while  fetal-placental  delivery  is 
therapeutic for HELLP syndrome. 
The association between TTP and SLE has been 
well recognized in clinical and histologic reports.
76
Severe  deficiency  of  ADAMTS13  activity  is 
predominantly  associated  with  the  presence  ofMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Table 4: Pathophysiologic classification of primary and secondary thrombotic microangiopathies.
Immune Mediated Non Immune Mediated
Primary
 Idiopathic TTP
 Atypical HUS secondary to inhibitory antibodies 
to complement – regulating  proteins
Primary
 Hereditary TTP
 Hereditary  atypical  HUS  secondary  to  mutations  in 
complement – regulating proteins
Secondary
 Pregnancy
 Autoimmune disorders
 Infections
 Medications (clopidogrel, ticlopidine)
Secondary
 Malignant hypertension
 Solid organ transplantation
 HCT
 Metastatic tumors
 Medications (cyclosporine, tacrolimus, IFN-α, Mitomycin C)
Abbreviations: TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; 
HCT: hematopoietic cell transplantation; IFN-α: interferon alpha.
inhibitory anti-ADAMTS13 IgG. 
ADAMTS13 levels are not generally decreased 
with  infections  such  as  HIV,  suggesting  an 
alternative  mechanism  for  TMA  in  these 
patients.
77,78 Cases of TMA associated with severe 
ADAMTS13  deficiency  and  inhibitory  anti-
ADAMTS13 IgG have been reported with influenza 
A,
79 legionella pneumonia
80 and brucellosis.
81
Antibodies  that  inhibit  plasma  ADAMTS13 
have also  been  demonstrated  in  patients  with 
ticlopidine
82 or clopidogrel-associated TMA.
83 The 
immune  dysregulation  by  these  thienopyridine 
compounds  might  be  analogous  to  the  anti-RBC 
antibody  ‘escape’,  associated  with  the 
antihypertensive medication α-methyldopa.
84
The  most  frequent  concomitant  conditions 
associated with TMA forms presenting with normal 
or  mildly  reduced  levels  of  ADAMTS13  (greater 
than  10%  serum  activity)  are  malignant 
hypertension,
17 metastatic  tumors,
85 solid  organ 
transplantation,  HCT  (particularly  allogeneic 
transplants),  and  the  use  of  drugs  such  as 
cyclosporine, mitomycin, and α-interferon.
34
Despite having some features in common, TA-
TMA  differs from de  novo TTP  in  many  aspects 
including  the  absence  of  severe  ADAMTS13 
deficiency,  a  different  spectrum  of  clinical 
symptoms, poor response to plasma exchange, and 
the  lack  of  evidence  of  systemic  microthrombus 
formation.
15 Several small retrospective studies of 
TA-TMA  encompassing  a  total  of  33  HCT 
recipients  also  suggest  that  severe  ADAMTS13 
deficiency  may  be  rare  among  this  patient 
population.
86-88 Indeed, other prospective reports in 
HCT recipients suggest that the  majority of these 
patients  experience  only  a  mild  decrease  in 
ADAMTS13  activity  (usually  after  the  cytotoxic 
conditioning) that can persist for weeks; however, 
severe ADAMTS13 deficiency was rare.
89,90 These 
data  suggest  that,  unlike  idiopathic  TTP, 
ADAMTS13  deficiency  is  not  the  primary 
component of the pathophysiology of TA-TMA and 
other factors may play a more central role.
Role  of  endothelial  cell  injury: For  a  long  time, 
many  authorities  have  considered  endothelial  cell 
injury as the central and likely inciting factor that 
sustains  the  microangiopathic  process  in  TMA, 
including the post-transplantation state.  As early as 
1942,  Altschule
91 suggested  that  microvascular 
endothelial  cell  activation  was  the  primary  event 
causing  platelet  deposition  in  arterioles  and 
capillaries with secondary “clearance of enormous 
numbers  of  platelets  from  the  circulation”. 
Endothelial  cells  synthesize  many  substances 
involved in  coagulation and fibrinolysis  including 
vWF,  thrombomodulin,  tissue-type  plasminogen 
activator  (tPA),  plasminogen  activator  inhibitor 
(PAI-1), protein S, prostacyclin (PGI2), and nitrous 
oxide  (NO).  Alterations  in  the  concentration  of 
these  substances  have been reported  in  idiopathic 
TTP  and  TA-TMA.
92,93 Whether  these  alterations 
represent an initiating effect or simply are reflective 
of endothelial cell injury, remains elusive. Levels of 
vWF  antigen  and  soluble  thrombomodulin  were 
measured in patients with idiopathic TTP and TA-
TMA.
94 vWF  antigen  and  thrombomodulin  levels 
were elevated in both patient groups compared to 
controls.  Thrombomodulin  concentrations  were 
significantly  higher  in  TA-TMA  compared  to 
idiopathic  TTP,  supporting  a  role  for  endothelial 
cell damage in the former. Gordon and colleagues
95
demonstrated  that  protein  C  deficiency  correlated 
with  thrombotic  complications  in  patients 
undergoing  HCT.    Several  groups  have  reported 
elevated  plasma levels  of fibrinogen, tPA,  PAI-1, Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
vWF  antigen,  thrombomodulin,  and  intercellular 
adhesion  molecule  1  (ICAM-1).
96-100 Kanamori  et 
al.
100 proposed  that  measurement  of 
thrombomodulin levels on day 14 post-HCT may be 
useful  in  surveillance  for  TA-TMA.  Cohen  and 
colleagues
93 proposed that endothelial cell injury is 
pathognomonic  of  TA-TMA  as  well  after  they 
demonstrated  absent  endothelial  cell  PGI2 release 
and scanning electron microscopy (EM) evidence of 
endothelial cell damage with TMA after allogeneic 
HCT.   
In  1996,  Laurence  and  co-workers
101
demonstrated  that  plasma  from  four  acute  TTP 
patients  could  induce  apoptosis  of  cultured 
endothelial cells of microvascular but not of large-
vessel  origin.  Ultrastructural  changes  became 
apparent  within  30  minutes  after  exposure  of 
endothelial cells to TTP sera and fresh complement; 
virtually  every  cell  quickly  developed  numerous 
cytoplasmic  inclusions,  followed  by  complete 
cytoplasmic  and  nuclear  degeneration.  Apoptosis 
was independent of tumor necrosis factor-α (TNF-
α)  or  the  presence  of  CD36  on  microvascular 
endothelial  cells,  but  was  linked  to  the  rapid 
induction effect of Fas (CD95) on these cells. Use 
of  soluble  anti-Fas  antibodies  suppressed  the 
endothelial  cell  apoptosis  mediated  by  TTP 
plasma.
101
The  presence  of  circulating  endothelial  cells 
(CEC)  recently  has  been  recognized  as  a  useful 
marker of vascular damage. Usually absent in the 
blood  of  healthy  individuals,  CEC  counts  are 
elevated  in  diseases  marked  by  the  presence  of 
vascular insult.
102 Recently, another endothelial cell 
marker linked with vascular dysfunction has been 
identified.  Endothelial  cell  microparticles  (EMP) 
are  vesicles  formed  by  the  endothelial  cell 
membrane after injury or activation. The phenotypic 
profile  of  EMP can vary considerably, depending 
on whether  parent  cells  have  undergone  either 
activation  (abundant  CD62E
+)  or  apoptosis 
(predominantly  CD31
+).
103 Microparticle  (MP) 
formation  has  been  demonstrated  using  in  vitro
endothelial  cell  activation  by  cytokines  such  as 
TNF-α  and  interleukin  (IL)-1.
104 It  has  also  been 
demonstrated that EMP have procoagulant activity, 
defined by platelet factor 3 activity and tissue factor 
(TF).
105 In  prothrombotic  states,  Shet  et  al.
106
reported raised tissue-factor (TF)-positive EMP in 
patients  compared  with  controls  and  a  strong 
correlation  with  procoagulant  activity.  Increased 
production  of  EMP  has  been  demonstrated  in 
idiopathic  TTP.
107 There  are  few  data  concerning 
the  release  of  EMP  in  the  course  of  HCT  exist; 
however, a recent report suggests that EMP increase
in the setting of acute GVHD, but not immediately 
after  non-myeloablative  conditioning  regimens.
108
Increases  in  circulating  platelet- and  monocyte-
derived MP have also been observed in the post-
transplantation period, including in one case of TA-
TMA.
109
In  the  HCT  setting,  proposed  mechanisms  of 
endothelial  cell  injury  include  toxic  conditioning 
regimens  with  high-dose  chemotherapy,
110-114
TBI,
115 infections  (CMV,  HHV-6),
116,117 and 
GVHD.
96,98,117,118 Evidence of TA-TMA was found 
in  one  analysis  of  allogeneic  HCT  recipients 
receiving  cyclosporine  as  GVHD  prophylaxis  but 
not in those treated with methotrexate (MTX).
14 In 
addition,  other  calcineurin  inhibitors  (e.g., 
tacrolimus) used for GVHD prophylaxis have been 
associated  with  increased  production  of 
thromboxane (TX) A2 and decreased production of 
PGI2.
119,120 Addition  of  sirolimus  to  a  calcineurin 
inhibitor  has  been  associated  with  potentiation  of 
these  effects.
121 Data  from  renal  transplant 
recipients  developing  TA-TMA  on  an 
immunosuppressive  regimen  of  cyclosporine  and 
sirolimus  suggest  that  the  combination  of  these 
agents concomitantly targets the molecular control 
of cell death and repair at the EC level.
121 The end 
result  is  loss  of  endothelial  cell  integrity,  and 
generation of a proinflammatory, procoagulant state 
likely leading to predilection for secondary TMA.
Risk  factors  and  prognosis: Non-modifiable  risk 
factors for development of TA-TMA include female 
gender,  African  American  race,  and  older 
age.
36,122,123 Prior medical history of severe hepatic 
dysfunction  and  advanced  primary  disease  also 
increase  the  risk  of  developing  TA-TMA.
124,125
Treatment-related  risk  factors  include:  unrelated 
donor  transplants;
88,122-124,126-128 HLA-mismatched 
donors;
124 fludarabine-based  non-myeloablative 
conditioning  regimens;
88,129 busulfan  and  TBI 
myeloablative  conditioning.
25,123,130 The  incidence 
of TA-TMA did not differ according to graft source, 
e.g.  bone  marrow  versus  peripheral  blood.
122 As 
mentioned above, use of calcineurin inhibitors such 
as  cyclosporine,
14,126,131-133 tacrolimus,
24,130,132 and 
sirolimus
132,134,135 are  also  associated  with  the 
development  of  TA-TMA.  Infections  and  the 
development  of  GVHD  also  increase  the  risk  of 
developing  TA-TMA.
14,21,123,124,128 In  the  HCT 
patients,  non-transplantation  etiologies  of  TMA 
such as idiopathic TTP and HUS should always be 
considered in the differential diagnosis, as they may 
coexist  with  the  primary  hematologic  disease.  In Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
TA-TMA,  poor  prognostic  indicators  include: 
patient  age  >  18  years,  a  graft  source  from  an 
unrelated  or  haploidentical  donor,
123 at  least  five 
schistocytes  per  high-power  field  on  peripheral 
film,
136 TA-TMA in the absence of sirolimus,
134 and 
nephropathy.
122 Specifically,  Uderzo  and 
coworkers
123 reported  three  factors  statistically 
significant  in  predicting  outcome  of  TA-TMA: 
adult age, unrelated or haploidentical graft source, 
and high TMA index (elevated LDH-platelet ratio). 
A  retrospective  cohort  analysis  of  myeloablative 
allogeneic  HCT  recipients  showed  that  sirolimus 
exposure  constitutes  a  risk  factor  for  the 
development of TA-TMA (10.8% in the sirolimus-
exposed  subjects  vs.  4.2%  in  the  non-sirolimus 
group)
134 but is also a favorable prognostic indicator 
in  terms of TA-TMA overall survival  (58.3% for 
TA-TMA related to sirolimus exposure vs. 11.1% in 
the  non-sirolimus  group)
134 and  renal  recovery 
(92%  vs.  78%  respectively).
134 Martinez  and 
colleagues
136 reported  lower  one-year  survival  in 
patients with TA-TMA than in patients without TA-
TMA  (27  ±  18.1%  for  TA-TMA  with  high 
schistocyte  counts;  53  ±  15%  for  TA-TMA  with 
low  schistocyte  counts;  vs.  78  ±  7%  in  patients 
without  TA-TMA,  p<  0.0001).  A  survey  of  the 
European  Group  for  Blood  and  Marrow 
Transplantation (EBMT)
122 conducted among forty-
five centers included 406 patients transplanted, and 
reported  an  incidence  of  TA-TMA  of  6.7%.  The 
only factor predictive of resolution of TA-TMA was 
the absence of nephropathy.
122
Therapeutic modalities
At the present time there is no consensus on what 
constitutes  appropriate  therapy  for  patients  with 
TA-TMA.  Initial  attempts  should  focus  on  the 
following:  i)  eliminating  possible  causative 
conditions  such  as  treating  underlying  infections 
and controlling acute GVHD; and ii) pharmacologic 
therapy  with  medications  such  as  daclizumab, 
defibrotide and rituximab. The rationale for use of 
these agents is based on empirical benefit 
Eliminating  Risk  Factors  and  Consideration  of 
Plasma  Exchange: Cyclosporine,  tacrolimus  and 
sirolimus should be discontinued immediately and 
replaced  with  alternative  immunosuppressive 
medications.  Corticosteroids,  mycophenolate 
mofetil, azathioprine and methotrexate can be used 
as  appropriate  alternatives.  Withdrawal  of 
cyclosporine  with  initiation  of  plasma 
exchange/apheresis has shown response rates of up 
to  63%.
137 In all  reported  cases  cyclosporine was 
discontinued at the time of diagnosis of TA-TMA, 
and the effect of this intervention in isolation cannot 
be  determined  as  patients  went  on  to  have 
therapeutic plasma exchange. 
Unlike  the  situation  in  idiopathic  TTP, 
responses to plasma exchange alone are suboptimal 
in TA-TMA. Reported response rates vary between 
0-49%,
138,139 compared  with  78-91%  in  patients 
with  idiopathic  TTP.
45,140 Further,  rise  in  platelet 
count,  the  usual  marker  for  response  to  plasma 
exchange,  cannot  be  relied  upon  in  TA-TMA 
because  platelet  engraftment  may  not  yet  have 
occurred. In addition, plasma exchange procedures 
are  associated  with  a  significant  number  of 
complications,  including  systemic  infections, 
catheter  thrombosis,  bleeding,  pneumothorax, 
pericardial  tamponade,  and  with  plasma  infusion, 
serum sickness and anaphylaxis.
Based  on  the  incomplete  responses  and  high 
complication rates, we do not advocate use of this 
procedure  but  rather  alternative  therapeutic 
approaches as discussed below.
Daclizumab: Daclizumab  is  a  humanized 
monoclonal anti-CD25 antibody, which targets the 
chain  of  the  IL-2  receptor.
141 This  agent  is  90% 
humanized,  retaining  only  10%  of  the  original 
murine compartments in the critical hypervariable 
segments  for  binding  specificity.  Daclizumab  has 
been  used  to  decrease  the  incidence  of  acute 
rejection  in  solid  organ  transplants  including 
renal,
142 hepatic,  cardiac,
143,144 and  lung 
transplantation.
143,145 Daclizumab  also  has  been 
used  successfully  in  T-cell  mediated  autoimmune 
diseases  such  as  multiple sclerosis,
146-148 pure  red 
cell aplasia,
149 and aplastic anemia.
150
In  the  HCT  setting,  intravenous  daclizumab 
(with a serum half-life of 20 days) has been used to 
prevent or treat acute GVHD;
151 more recently, this 
agent has been used for the treatment of TA-TMA. 
Adverse  effects  include  an  increased  risk  for 
bacterial,  candida  and  aspergillosis  infections,  as 
well  as  CMV  reactivation.  Through  its  effect  on 
depleting  alloreactive  T-cells,  daclizumab  can 
substitute for a calcineurin inhibitor. Wolff et al.
132
used  daclizumab  at  an  initial  loading  dose  of 
2mg/kg  and  then  1mg/kg  weekly.  Nine  of  13 
affected patients attained complete remission after 
therapy.
132 Four of the patients who had a complete 
remission from TMA also had complete resolution 
of active GVHD. A fifth, complete remitter patient 
from both TMA and GVHD died of primary disease 
relapse;  the  remaining  eight  patients  died  from 
infections, GVHD or multiorgan failure.
132 The long Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
half-life and potent immunosuppressive effect make 
this  agent  a  promising  treatment  modality  that 
merits further investigation.
Defibrotide: Defibrotide is a large, single-stranded 
polydeoxyribonucleotide,  derived  from  porcine 
mucosa by controlled depolymerization. It has been 
found to have potent anti-thrombotic, anti-ischemic, 
anti-inflammatory,  and  thrombolytic  properties, 
without  significant  systemic  anticoagulant 
effects.
127,152-158 This  drug  exerts  its  properties  by 
inhibition  of  TNFα-mediated  endothelial  cell 
apoptosis in vitro,
148 decreasing the activity of PAI-
1  and  increasing  endogenous  tissue  plasminogen 
activator (tPA) function.
159
Hepatic  veno-occlusive  disease  (VOD)  is  a 
potentially  lethal  complication  of  both  allogeneic 
and autologous HCT,
156,160,161 especially after prior 
exposure  to  the  immunoconjugate  gemtuzumab 
ozogamicin.
162 In  some  studies,  the  incidence  of 
hepatic  VOD  after  HCT  approaches  20%  with 
mortality  ranging  from  7%  to  50%.
163 The 
pathogenesis  of  VOD  involves  injury  to  the 
sinusoidal endothelial cells, leading to occlusion of 
small vessels with fibrin deposition and disruption 
of  hepatic  function.  Previous  attempts  at  therapy 
using  either  heparin  or  tPA  have  been 
unsuccessful.
164,165 Defibrotide  therapy  has 
improved outcomes for hepatic VOD that develops 
after HCT (30% to 60% CR rate).
166-170 Given the 
similarities  in  pathophysiology  with  TA-TMA, 
including  loss  of  small  vessel  endothelial  cell 
integrity, Corti and coworkers
155 reported that 3 of 
12  affected  patients  with  TA-TMA  given  oral 
defibrotide achieved partial remission, while 5 of 12 
patients achieved a complete response.
155 Because 
the effects of defibrotide are exerted locally within 
the vascular bed, it is usually well tolerated with no 
significant systemic effects on coagulation such as 
seen during treatment with tPA.
Rituximab: Rituximab, discussed above, has been 
used with increasing frequency for the treatment of 
various  hematologic  and  rheumatologic  disorders 
including idiopathic TTP,
171-173acquired coagulation 
factor  inhibitors,
174,175 antiphospholipid  antibody 
syndrome,
173 systemic  lupus  erythematosus
176 and 
rheumatoid  arthritis.
177,178 Rituximab  use  in 
relapsed, refractory TTP is linked to its ability to 
eliminate antibodies to ADAMTS13.
171 Au et al.
179
treated five TA-TMA patients refractory to a week
of  plasma  exchange  and  prednisolone  with 
rituximab  375mg/m
2/week  for  four  doses.  Four 
attained complete remission; two patients recovered 
after  receiving  two  weeks  of  rituximab.
179 At  a 
median follow-up of 305 days, 3 of 4 responders 
remained  in  remission
179 but  the  fourth responder 
died  of  sepsis.  The  only  non-responder  died  of 
multi-organ  failure  after  three  weeks.
179
ADAMTS13 antigen levels were marginal or low 
either post-HCT or at the onset of TMA and did not 
change  significantly  after  rituximab-induced 
remission.
179 It  remains  unclear  whether  these 
patients  actually  had  TA-TMA  (or  TTP),  thus 
making  the  use  of  rituximab  in  this  setting 
uncertain.  In  addition,  there  are  no  established 
guidelines for recommending duration of rituximab 
treatment.  Given the lack of reliable markers for 
remission  (serum  ADAMTS13  activity  and  anti-
ADAMTS13  antibody  levels),  maintenance 
rituximab therapy cannot be recommended.
  
Other  modalities  and  future  directions: Single 
agent  response  rates  for  the  antiplatelet  agents 
aspirin and dipyridamole approximate 10%,
49,180 a 
result indistinguishable from the natural history of 
TTP.  Antiplatelet  agents  have  not  been 
convincingly  shown  to  increase  the  response  to 
plasma exchange
45,51,181 and may promote bleeding 
in  the  setting  of  acute  thrombocytopenia  and 
invasive procedures.
51,182 Hence, their use as first-
line treatment of TMA, including TA-TMA, cannot 
be  recommended.  Although  not  verified  in  vivo, 
intravenous immunoglobulin (IVIG) has been used 
therapeutically  based  on  a  report that  IgG  from 
healthy  individuals  inhibits  the  capacity  of  TTP 
plasma to agglutinate platelets in vitro.
183 A recent 
study  described  a  response  to  the  combination of 
plasma exchange and IVIG in  a patient  who was 
refractory to  plasma exchange alone.
184 There  are 
anecdotal reports of favorable responses of TTP to 
vincristine,
180,185,186 as  well  as  other 
immunosuppressive therapies such as azathioprine, 
cyclophosphamid,  and  staphylococcal  protein  A 
immunoadsorption.
187,188 By analogy, there are case 
series of use of these agents in the setting of TA-
TMA.  Results  were disappointing and  difficult to 
interpret  since  all  of  the  patients  received 
concurrent therapy with plasma exchange.
128,139,189
On-going studies for further investigation of the 
pathogenesis of TA-TMA involve medications that 
modulate  the  endothelial  cell  inflammatory 
response.
190 These  agents  include  statins
190 and 
bosentan,
191 an endothelin receptor antagonist with 
protective  effects  in  in  vivo ischemia-reperfusion 
injury  models. Anti-oxidant  agents,  such as  nitric 
oxide donors which limit vascular injury caused by Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
free-radicals,  also  may  alter  the  course  of  the 
disease.    
Conclusions:  TA-TMA  is  an  uncommon  but 
devastating  complication  of  HCT.  Evidence 
suggests  that  it  represents  the  final  common 
pathway  of  multiple,  frequently  confounding 
variables  such  as  conditioning  regimens,  use  of 
calcineurin  inhibitors,  acute  GVHD  and 
opportunistic  infections.  The  elevated  blood 
concentrations of vWF antigen confirm endothelial 
cell injury. The typically incomplete responses and 
high  mortality  rates  call  for  better  therapeutic 
approaches. An alternative classification that takes 
into consideration the underlying pathophysiologic 
mechanisms  is  presented  here  and  should  limit 
diagnostic  uncertainty.  Accurate  diagnosis  is 
instrumental in designing future studies comparing 
management  strategies  and  outcomes  among 
different series. Treatment of TA-TMA consists of 
discontinuing  offending  agents  and  substituting 
calcineurin  inhibitors  with  daclizumab  or  other 
immunosuppressives. Due to questionable efficacy 
and  significant  associated  adverse  events,  plasma 
exchange, in general, is not recommended. Finally, 
monitoring  production  of  endothelial  cell 
microparticles or protein concentration changes of 
vWF, soluble  thrombomodulin,  and  PAI-1,  which 
occur in the setting of endothelial cell injury, may 
be useful in detecting early onset of TA-TMA. In 
line  with  these  considerations,  interventions 
directed  at  improving  endothelial  cell  function, 
accelerating  endothelial  cell  recovery  from  injury 
and preventing apoptosis of these cells are potential 
goals for future developmental therapies.
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